PMID- 34880797
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211211
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 12
DP  - 2021
TI  - Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia 
      With Predominantly Negative Symptoms.
PG  - 786171
LID - 10.3389/fpsyt.2021.786171 [doi]
LID - 786171
AB  - Negative symptoms of schizophrenia are among the most invalidating clinical 
      manifestations of this disorder, and they are correlated with poorer prognosis, 
      lower quality of life, and fewer chances for successful social reintegration and 
      professional rehabilitation. Although atypical antipsychotics have been 
      associated with higher efficacy on negative symptoms than typical agents, not all 
      of them are equally effective. Cariprazine is a new D3 and D2 receptor partial 
      agonist, and its high D3 affinity may be useful for decreasing several adverse 
      events (e.g., extrapyramidal symptoms or hyperprolactinemia), and also for 
      increasing this drug's efficacy over negative symptoms. This case series presents 
      three young adults with predominantly negative symptoms during treatment with an 
      atypical antipsychotic, administered in stable dose within the therapeutic range, 
      and for at least 4 weeks prior to the cariprazine switch. These patients (two 
      male and one female, mean age 35.7 years) were diagnosed with schizophrenia, 
      according to the DSM-5 criteria. They were evaluated using Positive and Negative 
      Syndrome Scale (PANSS), Clinical Global Impression-Severity (CGI-S), and Global 
      Assessment of Functioning (GAF). Their mean initial values were 80.3 on PANSS, 
      4.3 on CGI-S, and 48 on GAF. All these patients were already on a treatment with 
      stable doses of atypical antipsychotics (olanzapine 10 mg/day, n = 1, risperidone 
      6 mg/day, n = 1, and quetiapine 600 mg/day, n = 1). Cross-titration to 
      cariprazine was initiated, from 1.5 mg qd up to 6 mg qd, during a mean period of 
      2.7 weeks. After 12 weeks of cariprazine 6 mg/day, the positive scale of PANSS 
      was relatively stable compared to baseline, while the negative mean score 
      decreased by 22%. Also, the mean CGI-S improvement was 15.4% and the GAF mean 
      score increased by 17%. The overall tolerability was good, without severe adverse 
      events being reported. Conclusions: Cariprazine is well tolerated and efficient 
      for patients diagnosed with schizophrenia who have significant negative symptoms 
      that impair daily functioning. After 12 weeks cariprazine succeeded in improving 
      negative symptoms, global functioning, and clinical global impression.
CI  - Copyright (c) 2021 Vasiliu.
FAU - Vasiliu, Octavian
AU  - Vasiliu O
AD  - Department of Psychiatry, Dr. Carol Davila University Emergency Central Military 
      Hospital, Bucharest, Romania.
LA  - eng
PT  - Case Reports
DEP - 20211122
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC8645548
OTO - NOTNLM
OT  - cariprazine
OT  - negative symptoms
OT  - novel atypical antipsychotics
OT  - quality of life
OT  - schizophrenia
OT  - social reintegration
OT  - tolerability
COIS- The author declares that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/12/10 06:00
MHDA- 2021/12/10 06:01
PMCR- 2021/11/22
CRDT- 2021/12/09 06:59
PHST- 2021/09/29 00:00 [received]
PHST- 2021/10/22 00:00 [accepted]
PHST- 2021/12/09 06:59 [entrez]
PHST- 2021/12/10 06:00 [pubmed]
PHST- 2021/12/10 06:01 [medline]
PHST- 2021/11/22 00:00 [pmc-release]
AID - 10.3389/fpsyt.2021.786171 [doi]
PST - epublish
SO  - Front Psychiatry. 2021 Nov 22;12:786171. doi: 10.3389/fpsyt.2021.786171. 
      eCollection 2021.